These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 2879447)
1. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447 [TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995. Anderson JV; Bloom SR Scand J Gastroenterol Suppl; 1986; 119():115-28. PubMed ID: 2876495 [TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Kvols LK; Buck M; Moertel CG; Schutt AJ; Rubin J; O'Connell MJ; Hahn RG Ann Intern Med; 1987 Aug; 107(2):162-8. PubMed ID: 2886085 [TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion. Williams G; Anderson JV; Williams SJ; Bloom SR Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335 [TBL] [Abstract][Full Text] [Related]
5. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. Eriksson B; Oberg K; Andersson T; Lundqvist G; Wide L; Wilander E Scand J Gastroenterol; 1988 May; 23(4):508-12. PubMed ID: 2898168 [TBL] [Abstract][Full Text] [Related]
6. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Gorden P; Comi RJ; Maton PN; Go VL Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688 [TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs in the management of gastrointestinal tumors. Lamberts SW Horm Res; 1988; 29(2-3):118-20. PubMed ID: 2900191 [TBL] [Abstract][Full Text] [Related]
8. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas. Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819 [TBL] [Abstract][Full Text] [Related]
9. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms. Ahlman H; Tisell LE Scand J Gastroenterol; 1987 Oct; 22(8):938-42. PubMed ID: 2891186 [TBL] [Abstract][Full Text] [Related]
10. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma. Koelz A; Kraenzlin M; Gyr K; Meier V; Bloom SR; Heitz P; Stalder H Gastroenterology; 1987 Feb; 92(2):527-31. PubMed ID: 2878857 [TBL] [Abstract][Full Text] [Related]
11. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Souquet JC; Sassolas G; Forichon J; Champetier P; Partensky C; Chayvialle JA Cancer; 1987 May; 59(9):1654-60. PubMed ID: 2435403 [TBL] [Abstract][Full Text] [Related]
12. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors. Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958 [TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Vinik AI; Tsai S; Moattari AR; Cheung P Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562 [TBL] [Abstract][Full Text] [Related]
14. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome. Mozell E; Woltering EA; O'Dorisio TM; Fletcher WS; Sinclair AJ; Hill D Surg Gynecol Obstet; 1990 Jun; 170(6):476-84. PubMed ID: 2188384 [TBL] [Abstract][Full Text] [Related]
15. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948 [TBL] [Abstract][Full Text] [Related]
16. Effect of somatostatin analogue (SMS 201-995) on molecular species of gastrin in gastrinoma. Campagnolo D; Gower WR; Fabri PJ; Sparks J; Mekhjian HS; O'Dorisio TM; Ellison EC Surgery; 1987 Dec; 102(6):982-7. PubMed ID: 2891204 [TBL] [Abstract][Full Text] [Related]
17. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide]. Arnold R; Neuhaus C; Trautmann ME Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235 [No Abstract] [Full Text] [Related]
18. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Kraenzlin ME; Ch'ng JL; Wood SM; Carr DH; Bloom SR Gastroenterology; 1985 Jan; 88(1 Pt 1):185-7. PubMed ID: 2856877 [TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogue SMS 201-995 long term therapy for vipoma. Juby LD; Burke DA; Axon AT Postgrad Med J; 1987 Apr; 63(738):287-9. PubMed ID: 2891127 [TBL] [Abstract][Full Text] [Related]
20. Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Lamberts SW; Pieters GF; Metselaar HJ; Ong GL; Tan HS; Reubi JC Acta Endocrinol (Copenh); 1988 Dec; 119(4):561-6. PubMed ID: 2849276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]